Interstitial lung disease (ILD) is a severe and frequent extraarticular manifestation of rheumatoid arthritis (RA). A higher mortality rate in patients with RA-ILD in comparison with those without ILD has been widely reported [1]. The presence of lung involvement itself implies a worse prognosis, however, the evolution of RA-ILD patients depends on several factors such as age, lung function, radiological pattern, number of acute exacerbations or different serum biomarkers [2]. Furthermore, the delay of ILD diagnosis in RA patients, and subsequently in their treatment, increases the mortality in this population [3].
